Multiple Myeloma

Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation

February 8th 2023

Dr Ajai Chari explains the mechanism of action of BCMA-targeting bispecifics and the role of teclistamab in multiple myeloma treatment.

Induction Therapy in Transplant-Ineligible NDMM

February 8th 2023

Anne-Marie Jacob describes her early treatment regimen for multiple myeloma and her experience with clinical trial enrollment.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Role of Transplant and Induction Therapies in NDMM

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Selecting Treatment Regimens for Multiple Myeloma at First Relapse

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

Choosing the Right Treatment for Patients With Transplant Ineligible MM

Turning to the last module, expert panelists discuss the treatment armamentarium for patients experiencing early relapse in multiple myeloma.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

Clinical Pearls and Unmet Needs in R/R Multiple Myeloma

Patient and disease factors that help to select best first-line therapy in the setting of transplant-ineligible multiple myeloma.

The Genetics of Multiple Myeloma: Expert Perspectives

February 3rd 2023

Joshua Richter, MD, offers advice to community oncologists and discusses unmet needs in the treatment of patients with relapsed/refractory MM.

ONCOLOGY Staff

February 2nd 2023

Experts discuss the genetics of multiple myeloma, the prevalent testing paradigms in this space, and possibilities for the future.

Treatment Duration in Patients With Transplant-Ineligible NDMM

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

Transplant-Ineligible NDMM: Optimizing Therapy for Frailer Patients

Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

Resources for Patient Education

Experts from the Moffit Cancer Center work to identify frail patients with transplant-ineligible NDMM and consider how best to select first-line therapy for this population.

A Patient’s Experience With a Multiple Myeloma Diagnosis

Nurse Practitioner Kiah Purcell and Registered Nurse Annel Urena explain their role in the diagnosis and education of a patient with multiple myeloma.

DETERMINATION, GRIFFIN, and MASTER Studies

Ajai Chari, MD, provides a quick overview of multiple myeloma and patient Anne-Marie Jacob shares the story of her diagnosis.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Induction Regimen Options in Transplant-Eligible NDMM

Expert panelists discuss recent data updates from the DETERMINATION, GRIFFIN, and MASTER studies.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Approaching Induction Therapy for Patients With Transplant-Ineligible MM

Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

Selecting The Appropriate Treatment in Transplant-Eligible Newly Diagnosed MM

Switching their focus to transplant-ineligible multiple myeloma, panelists review available triplet therapy regimens for induction therapy.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

Bispecific Antibodies in the Treatment of Multiple Myeloma

A brief discussion how to select the appropriate treatment strategy in transplant-eligible newly diagnosed myeloma and whether there is a role for minimal residual disease in assessing response and treatment duration.

Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple-Class Refractory MM

January 27th 2023

An expert oncologist evaluates the effect of combination trials of bispecific antibodies on the multiple myeloma treatment landscape.

Bispecific Antibodies in Relapsed/Refractory MM: Future Perspectives

January 27th 2023

An overview of recent data on selinexor, carfilzomib, and dexamethasone in triple-class refractory multiple myeloma, and treatment options to replace belantamab.

Ajai Chari, MD;Krina Patel, MD;Alfred Garfall, MD;Sham Mailankody, MD

January 26th 2023

Closing out their discussion on the treatment paradigm of relapsed/refractory multiple myeloma, key opinion leaders highlight key takeaways and future directions in care.

Appropriate Patient Selection for Cevostamab in Relapsed/Refractory MM

Ajai Chari, MD;Krina Patel, MD;Alfred Garfall, MD;Sham Mailankody, MD

January 26th 2023

Shared insight on possible real-world applications for FcRH5-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

Selecting First-Line Therapy for Patients With Transplant-Ineligible NDMM

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

January 25th 2023

Moving on to review the management of transplant-ineligible NDMM, expert panelists highlight first-line treatment options with data from the SWOG0777 and MAIA studies.

Patient Profile 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

January 25th 2023

Centering focus on a patient scenario of transplant-eligible newly diagnosed multiple myeloma, panelists consider the role of induction therapy and transplant in this setting.

Selection of Induction Therapy in Patients With Transplant-Eligible NDMM

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

Role of Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

Shared insight from experts in multiple myeloma on the real-world utilization of induction therapy and transplant for patients with newly diagnosed disease.

Transplant-Eligible NDMM: Overview of Available Induction Therapies

Expert oncologist Joshua Richter, MD, defines triple-class refractory multiple myeloma and describes selinexor’s unique mechanism of action.

Melissa Alsina, MD;Ken Shain, MD, PhD;Rachid Baz, MD;Brandon Blue, MD

Overview of Multiple Myeloma and Treatment Options

Experts from the Moffit Cancer Center share insight on induction therapy strategies and optimization for patients with transplant-eligible newly diagnosed multiple myeloma.

Should Every Patient With Newly Diagnosed MM Receive a Transplant?

Joshua Richter, MD, gives an overview of treatment options in multiple myeloma and factors that influence treatment decisions.

Sagar Lonial, MD;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

The Evolving Treatment Landscape of Transplant-Eligible Newly Diagnosed Multiple Myeloma

In light of recent clinical trial data, key opinion leaders reflect on the appropriate selection of transplant for patients with newly diagnosed multiple myeloma.

Sagar Lonial, MD;Caitlin Costello, MD;Sandy Wong, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD